Navigation Links
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
Date:4/18/2008

SMYRNA, Ga., April 18 /PRNewswire/ -- Data presented today at a platform session of the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago support the potential for adjunctive use of intravenous lacosamide 200-600 mg/day using infusion durations as fast as 10 minutes for short term replacement of oral lacosamide in adult patients with partial onset seizures.

Regulatory filings for lacosamide oral tablet, oral syrup and intravenous formulation are currently under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.

"When patients are temporarily hospitalized or undergo surgical procedures making it difficult to swallow, they may not be able to take their oral antiepileptic drug. In these circumstances, and in order to maintain seizure control, a short-term, alternative administration of their antiepileptic medication is desirable," said Gregory Krauss, MD, Department of Neurology, Johns Hopkins Epilepsy Center, Baltimore. "In this study, short-term intravenous therapy with lacosamide was well tolerated when substituted for oral lacosamide treatment in patients with certain epilepsy types."

The study was a multi-center, multi-national, open-label trial of 160 patients who were receiving oral lacosamide for at least eight weeks. For the last two weeks of the trial, these patients were on a stable twice daily dosing regimen of lacosamide (200-800 mg/day), as well as concomitant antiepileptic drugs with or without vagus nerve stimulation. During the treatment period (two to five days), oral lacosamide was replaced with intravenous lacosamide, infused at a rate of 10, 15 and 30 minutes.

Intravenous lacosamide was generally well-tolerated and the frequency of adverse events did not increase with more days of exposure or shorter infusion durations. The incidence of adverse events
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
2. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
7. PG500 Series Presented at the AACR Annual Meeting in San Diego
8. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ctober 7 /-,Sosei Group Cor...ctura,Group plc ("Vectura"; LSE: VEC), announce re...acy, safety and tolerability of NVA237 presented a...Society (ERS) in Berlin,Germany. The new data sho...haled long-acting muscarinic antagonist (LAMA), pr...
(Date:10/6/2008)...to the understanding of and possible trea...BILLERICA, Mass., Oct. 6 /- Seahorse ...t ever analytical instrument for the,kinetic measu...oplasmic,glycolysis in cells in a 96 well micropla...ular bioenergetics have been relatively unchanged ...
(Date:10/6/2008)... at The American College of Nutrition ...6 /- New research on the benefits of,...t The American College of,Nutrition (ACN) Annual M...Probiotics in Health and Disease." Scientific expe...ion discussed the potential uses for,probiotics in...
(Date:10/6/2008)...E, Oct. 6 /- Complete,Genomics Inc., ...quencing,company, and the Institute for Systems Bi...onduct populationwide human genome studies., In p...e its proprietary,DNA sequencing technology to seq...hen, once proof-of-concept has been demonstrated, ...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 1New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 3Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 1Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 2Research suggests new treatment suitable for all patients 8954 1Research suggests new treatment suitable for all patients 8954 2Research suggests new treatment suitable for all patients 8954 3Silence may lead to phantom noises misinterpreted as tinnitus 8952 1
(Date:10/7/2008)... Moores Cancer Center at the University of Califor...ave off the relentless march of advanced lung canc...r vaccine. While many vaccines attempt to pump up ...accine, Lucanix, is genetically engineered to also...em-suppressing activities. , The first patients ...
(Date:10/7/2008)...ment of planned bequest comes at stem cell symposi...re/ -- Just over one year,ago, retail pioneer A. A...University of Michigan, to endow a new research in...nting human disease., Today, at the institute,s f... he will bequeath an additional $22 million to the...
(Date:10/7/2008)...0 PEOPLE ACROSS THE NATION HAVE SAID ,I VOTE FOR T...S, Oct. 7 /PRNewswire/ -- To aid and help educate ... positions of presidential candidates,Senators Joh...ancer issues,the Susan G. Komen for the Cure(R) A...ces available on its web site --, http://www.IVote...
(Date:10/7/2008)... Wyndstorm Corporation ( www.wyndstorm.com ) ...ompany, announced a key win with Muve, Inc. ( www....plan program design to promote Muve,s activity-bas...project will ultimately help Muve,s corporate clie...oyees via interactive messaging, rewards programs,...
Breaking Medicine News(10 mins):Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
...claim to the highest autism rate in America, have ...to autism and provide lifetime care for those wit...utism, the largest so far, has found that about 1 ...est rate 1 in 94 children found in New Jersey. ...
...tronic nose device which may be used to diagnose t...s at Leiden University Medical Center in the Nethe... a newer version of a sensor that has been used in...es, contains chemical vapour sensors that react to...
...male impotence drug Viagra may be useful for treat...r the treatment of high blood pressure and angina,...levels of a naturally-occurring compound, cyclic g...GMP). In the brain, cGMP has a vital function in ...
...that topical application of a gel made from platel...ds heal more quickly and completely . Recent inno... into a concentrated plasma rich in platelets (par...), and then to an autologous (from the patients ow...
Other Medicine News:Health News:American State Lawmakers Make Moves To Tackle Autism 2Health News:Electronic Nose to Diagnose the Severity of Asthma 2Health News:Gel Made of Patients Own Platelets may Speed Up Wound Healing 2
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: